Status:
COMPLETED
Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)
Lead Sponsor:
Chugai Pharmaceutical
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
20-75 years
Phase:
NA
Brief Summary
This is an open-label, clinical pharmacology study to investigate drug-drug interaction in patients with RA.
Eligibility Criteria
Inclusion
- Inclusion criteria
- Patients who are diagnosed with RA according to the 1987 American College of Rheumatology (ACR) classification criteria
- Patients who contracted RA at least 6 months prior
- Exclusion criteria
- Patients with Class IV Steinbrocker functional impairment at enrollment.
- Patients who have been treated for the underlying disease with a biological agent, such as infliximab or etanercept and have been receiving treatment with leflunomide, within 12 weeks before initiation of treatment with the probe drug
Exclusion
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2005
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT00144560
Start Date
February 1 2005
End Date
August 1 2005
Last Update
December 15 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.